Corin Group Launches Trinity(TM) Dual Mobility System for Hip Replacement at AAOS 2018 Annual Meeting
NEW ORLEANS, March 6, 2018 /PRNewswire/ -- Corin, a global orthopaedic manufacturer and leader in functional implant positioning, today announced the launch of the Trinity™ Dual Mobility System featuring new implant technology designed to improve range of motion and reduce the risk for instability and dislocation after primary or revision hip replacement. The announcement was made here at the American Academy of Orthopaedic Surgeons (AAOS) 2018 Annual Meeting.
The system is designed for use with Corin's Optimized Positioning System (OPS™), an innovative technology that helps surgeons determine the best positioning and orientation of a hip implant based on a dynamic preoperative functional assessment and analysis of each patient.
"Dual mobility systems have emerged to better address instability and dislocation after total hip replacement," said orthopaedic surgeon Douglas Dennis, MD* of Colorado Joint Replacement in Denver. "The Trinity Dual Mobility System, when used with OPS technology, may go even further in addressing these issues by helping surgeons achieve optimal functional implant positioning, which has a significant impact on patient outcomes."
The Trinity Dual Mobility System is a modular acetabular system that puts two articulating surfaces in the same joint space to provide patients with increased stability, multi-directional movement and a greater range of motion compared to conventional hip replacement.
The system is manufactured using Corin's ECIMA™ polyethylene to help reduce the risk of in-vivo oxidation. Its proprietary design allows for a self-centering of the polyethylene liner during normal gait cycles, which reduces load and eliminates the risk of impingement between stem and polyethylene. Also, surgeons have the ability to orient the liner and decide the location of the elevated portion of the lip for an increase in jump height and greater range of motion.
"Dual mobility and optimized functional positioning is a powerful combination that will help me better tailor the operation to the patient and improve outcomes," said Stephen Raterman, MD,* an orthopedic surgeon at Florida Hospital in Tampa.
"We continue to respond to the needs of orthopaedic surgeons and their patients with clinically-proven procedural solutions that may help improve outcomes and increase patient satisfaction," said Paul Berman, President, Corin USA.
About Corin Group
Corin is a European orthopaedic manufacturer based in the UK that markets its products throughout the world.
Corin is committed to:
…improving patient satisfaction with personalized technologies that optimize our clinically proven joint replacements
…delivering a personal approach to our customers, combining the spirit of our local companies with the strength of our global, integrated organization
…empowering and rewarding our global talented teams to deliver excellence to our customers
For further information about Corin, please visit www.coringroup.com.
*Paid consultant to Corin
This news release contains forward-looking statements. These statements appear in a number of places in this news release and include statements regarding our intentions, beliefs or current expectations, concerning, among other things, our results of operations, turnover, financial condition, liquidity, prospects, growth, strategies, new products, the level of new launches and the markets in which we operate. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ markedly from those in the forward-looking statements as a result of various factors. We undertake no obligation publicly to revise any forward-looking statements, except as may be required by law.
View original content with multimedia:http://www.prnewswire.com/news-releases/corin-group-launches-trinity-dual-mobility-system-for-hip-replacement-at-aaos-2018-annual-meeting-300608989.html
Upcoming Life Sciences Events
- September 2018
- Boston: Discovery on Target, DOT
- Pudong Xinqu: Tumor Models Shanghai
- Brussels: The Pharma Business Development Course - An Overview Course